Highest-materiality recent filing
MariMed reports FY2025 revenue of $159.8M, net loss widens to $14.5M, adjusted EBITDA down to $16.9M
FY2025 revenue $159.8M, up from $157.7M in FY2024; Q4 revenue $41.7M vs $38.9M.
MariMed restructures $14.2M Series B obligation with $8M notes and 26.9M preferred shares
Old Series B preferred (4,908,333 shares) cancelled, avoiding ~$14.2M cash payout upon mandatory conversion on Feb 28, 2026.
MariMed Q3 revenue $40.8M, adjusted EBITDA $5.1M; expands brands to 3 new states
Revenue flat at $40.8M (Q3 2024: $40.6M); GAAP net loss widened to $2.9M from $1.0M.
MariMed Q2 revenue $39.6M, adjusted EBITDA $4.9M; net loss narrows YoY
Revenue of $39.6M for Q2 2025, down 2% YoY from $40.4M; GAAP net loss improved to $1.3M from $1.6M.
MariMed Q1 revenue flat at $38.0M; net loss widens to $5.4M from $1.3M YoY
Revenue of $38.0M flat vs $37.9M a year ago; GAAP gross margin fell to 40% from 43%.
MariMed reports record FY2024 revenue $158M; Q4 margins compress, adjusted EBITDA up in Q4
Q4 2024 revenue $39.0M (vs $38.9M); full-year revenue $158.0M (+6.3% YoY).
MariMed Q3 revenue up 5% to $40.6M; net loss narrows to $1.0M
Revenue $40.6M, +5% YoY; adjusted EBITDA $4.7M vs $6.1M in Q3 2023.
MariMed Q2 2024 revenue $40.4M, GAAP net loss $1.6M, adjusted EBITDA $4.4M
Revenue $40.4M, up 10.7% YoY from $36.5M; gross margin 42% (GAAP), 43% (non-GAAP).
MariMed Q1 2024 revenue up 10% to $37.9M; net loss widens to $1.3M, adjusted EBITDA down
Revenue of $37.9M (+10% YoY); GAAP gross margin 43% vs 45% in prior year.
MariMed Q4 revenue $38.9M (+8.6% YoY); GAAP net loss $10.1M; announces MD dispensary acquisition
Q4 2023 revenue $38.9M, up 8.6% from $35.8M in Q4 2022; full year revenue $148.6M, up 10.9% from $134.0M.
Effective August 9, 2024, MariMed Inc. (the “Company”) appointed Mario Pinho as the Company's Chief Financial Officer to replace Jon Levine, the Company's Interim Chief Financial Officer.
Max materiality 0.85 · Median 0.65 · Most common event earnings